LifeCycle Pharma Announces Successful Completion of Pilot Studies on LCP-Feno and is Currently Preparing for Pivotal Studies

Published: May 28, 2008

HORSHOLM, Denmark--(BUSINESS WIRE)--LifeCycle Pharma A/S (OMX:LCP) today announced the successful completion of pilot studies for LCP-Feno, a product for the treatment of dyslipidemia which is being developed in collaboration with Sandoz Inc. LCP-Feno is designed to be an AB-rated, substitutable version of Tricor® 145 mg, currently marketed in the US by Abbott under the name Tricor® and in Europe by Solvay S.A. under the name Lipanthyl ®. In collaboration with Sandoz, LifeCycle Pharma is currently preparing for the initiation of pivotal studies to complete all the necessary requirements for a US ANDA filing.

Back to news